TCON

TRACON Pharmaceuticals, Inc. [TCON] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TCON Stock Summary

Top 10 Correlated ETFs

TCON


Top 10 Correlated Stocks

TCON


In the News

08:00 08 Jun 2023 TCON

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

SAN DIEGO, June 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 am Eastern Time.

10:18 08 Jun 2023 TCON

TRACON Pharmaceuticals, Inc. (TCON) Q1 2023 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Edward White - H.C. Wainwright & Co., LLC Joel Beatty - Robert W.

09:11 08 Jun 2023 TCON

Why Is TRACON Pharma (TCON) Stock Down 51% Today?

TRACON Pharmaceuticals (NASDAQ: TCON ) stock is falling on Tuesday following an update on a legal battle with I-Mab  (NASDAQ: IMAB ). The bad news for TCON stock comes from a legal ruling favoring I-Mab.

01:44 08 Jun 2023 TCON

Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade

Tracon (TCON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

08:00 08 Jun 2023 TCON

TRACON Pharmaceuticals, Inc. (TCON) Q4 2022 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Soumit Roy - Jones Research Joel Beatty - Robert W. Baird & Co. Robert Hazlett - BTIG Operator Good day, ladies and gentlemen, and welcome to TRACON Pharmaceuticals Fourth Quarter and Year Ended 2022 Earnings Conference Call.

04:02 08 Jun 2023 TCON

TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its fourth quarter and year-end 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2023. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

01:52 08 Jun 2023 TCON

5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts

Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

01:43 08 Jun 2023 TCON

Revisiting Tracon Pharmaceuticals

Today, we look back in on clinical stage developmental firm TRACON Pharmaceuticals for the first time since early 2021. The company's primary drug candidate Envafolimab could provide certain advantages over other approved PD-L1 inhibitors.

08:41 08 Jun 2023 TCON

TRACON Pharmaceuticals doses first patient in drug trial to treat malignant tumours

TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has dosed the first patient in a Phase 1/2 trial evaluating the company's CTLA-4 antibody, YH001, in combination with its PD-L1 antibody envafolimab and with doxorubicin, in front line therapy of patients with malignant tumours. The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma sub-types of leiomyosarcoma and dedifferentiated liposarcoma, according to TRACON.

10:43 08 Jun 2023 TCON

TRACON Pharmaceuticals, Inc. (TCON) Q3 2022 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Charles Theuer - CEO, President & Director Scott Brown - CFO Conference Call Participants Joel Beatty - Robert W. Baird & Co. Edward White - H.C.

TCON Financial details

Company Rating
Neutral
Market Cap
15.29M
Income
-30.82M
Revenue
0
Book val./share
-0.47
Cash/share
0.28
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
08 Aug 2023
P/E
-0.48
Forward P/E
-
PEG
0.29
P/S
-
P/B
-1.35
P/C
2.15
P/FCF
-0.64
Quick Ratio
0.47
Current Ratio
0.5
Debt / Equity
-1.75
LT Debt / Equity
-
-
-
EPS (TTM)
-1.39
EPS next Y
-
EPS next Q
-
EPS this Y
-16.17%
EPS next Y
-
EPS next 5Y
783.45%
EPS last 5Y
-35.96%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
43.75%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-50%
Inst Own
47.56%
Inst Trans
1.81%
ROA
-370%
ROE
673%
ROC
4.4%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
26.48M
Shs Float
14.55M
-
-
-
-
Target Price
-
52W Range
0.55-2.32
52W High
-
52W Low
-
RSI
34
Rel Volume
0.17
Avg Volume
188.13K
Volume
31.41K
Perf Week
-2.51%
Perf Month
-21.55%
Perf Quarter
-53.29%
Perf Half Y
-58.16%
-
-
-
-
Beta
1.35257
-
-
Volatility
0.01%, 0.05%
Prev Close
-4.37%
Price
0.6025
Change
-2.71%

TCON Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
1.11000.020
Net income per share
-12.97-7.46-1.87-1.67-1.4
Operating cash flow per share
-11.42-7.79-1.9-1.31-1.25
Free cash flow per share
-11.42-7.79-1.9-1.31-1.26
Cash per share
14.515.414.021.40.83
Book value per share
7.960.892.790.68-0.34
Tangible book value per share
7.960.892.790.68-0.34
Share holders equity per share
7.960.892.790.68-0.34
Interest debt per share
2.471.890.560.110.52
Market cap
16.98M7.1M105.11M47.79M31.17M
Enterprise value
-1.73M-3.97M77.51M25.26M23.54M
P/E ratio
-0.49-0.31-6.26-1.66-1.06
Price to sales ratio
5.6600138.120
POCF ratio
-0.55-0.3-6.17-2.12-1.19
PFCF ratio
-0.55-0.3-6.17-2.11-1.19
P/B Ratio
0.792.634.194.08-4.36
PTB ratio
0.792.634.194.08-4.36
EV to sales
-0.580072.990
Enterprise value over EBITDA
0.050.18-4.78-0.89-0.84
EV to operating cash flow
0.060.17-4.55-1.12-0.9
EV to free cash flow
0.060.17-4.55-1.12-0.9
Earnings yield
-2.06-3.19-0.16-0.6-0.94
Free cash flow yield
-1.81-3.33-0.16-0.47-0.84
Debt to equity
0.95.720.491.27-3.72
Debt to assets
0.470.850.330.561.37
Net debt to EBITDA
0.540.51.70.790.27
Current ratio
3.011.463.51.820.81
Interest coverage
-150.39-57.76-29.77-89.14-28.06
Income quality
0.881.041.020.790.9
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.430050.710
Research and developement to revenue
10.150032.210
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
000-0.140
Capex to depreciation
000.380.81-0.24
Stock based compensation to revenue
0.89005.130
Graham number
48.212.2210.835.043.28
ROIC
3.611.510.571.071.45
Return on tangible assets
-0.86-1.25-0.45-1.08-1.51
Graham Net
7.380.332.650.53-0.44
Working capital
27.11M5.43M26.37M11.26M-4.14M
Tangible asset value
21.44M2.7M25.07M11.71M-7.15M
Net current asset value
21.4M1.84M24.55M10.09M-8.39M
Invested capital
0.31.980.180.13-1.37
Average receivables
00000
Average payables
00862.5K3.33M4.43M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.63-8.4-0.67-2.454.1
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
Revenue per share
00000
Net income per share
-0.48-0.31-0.3-0.32-0.46
Operating cash flow per share
-0.34-0.4-0.32-0.21-0.21
Free cash flow per share
-0.34-0.4-0.32-0.21-0.21
Cash per share
0.850.670.790.780.28
Book value per share
0.140.13-0.12-0.32-0.47
Tangible book value per share
0.140.13-0.12-0.32-0.47
Share holders equity per share
0.140.13-0.12-0.32-0.47
Interest debt per share
0.0400.430.480.05
Market cap
51.57M40.54M35.85M33.22M44.8M
Enterprise value
35.63M26.96M27.91M25.59M38.19M
P/E ratio
-1.36-1.63-1.38-1.15-1.03
Price to sales ratio
00000
POCF ratio
-7.65-5.06-5.25-7.14-8.95
PFCF ratio
-7.64-5.06-5.25-7.13-8.95
P/B Ratio
18.4815.95-13.61-4.65-4.05
PTB ratio
18.4815.95-13.61-4.65-4.05
EV to sales
00000
Enterprise value over EBITDA
-3.77-4.34-4.42-4.39-5.23
EV to operating cash flow
-5.28-3.36-4.09-5.5-7.63
EV to free cash flow
-5.28-3.36-4.08-5.5-7.63
Earnings yield
-0.18-0.15-0.18-0.22-0.24
Free cash flow yield
-0.13-0.2-0.19-0.14-0.11
Debt to equity
5.765.17-8.46-3.72-1.75
Debt to assets
0.850.841.131.372.33
Net debt to EBITDA
1.692.191.261.310.9
Current ratio
1.161.171.530.810.5
Interest coverage
-363.31-779.88-109.95-6.35-6.16
Income quality
0.711.291.060.660.59
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0.15-0.08-0.11-0.360
Stock based compensation to revenue
00000
Graham number
1.250.930.911.532.2
ROIC
0.660.280.450.311.91
Return on tangible assets
-0.5-0.4-0.33-0.37-1.31
Graham Net
0.030.02-0.25-0.41-0.54
Working capital
2.34M2.09M6.26M-4.14M-7.04M
Tangible asset value
2.79M2.54M-2.64M-7.15M-11.07M
Net current asset value
1.22M1.02M-4.28M-8.39M-12.26M
Invested capital
0.250-3.45-1.370
Average receivables
00000
Average payables
2.47M5.5M5.5M1.96M1.96M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-3.41-2.442.461.010.98
Capex per share
00000

TCON Frequently Asked Questions

What is TRACON Pharmaceuticals, Inc. stock symbol ?

TRACON Pharmaceuticals, Inc. is a US stock , located in San diego of Ca and trading under the symbol TCON

What is TRACON Pharmaceuticals, Inc. stock quote today ?

TRACON Pharmaceuticals, Inc. stock price is $0.6025 today.

Is TRACON Pharmaceuticals, Inc. stock public?

Yes, TRACON Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap